Immune Therapeutics, Inc. (OTCMKTS:IMUN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On January 2, 2019, the directors of Immune Therapeutics, Inc., a Florida corporation (the “Company” or “IMUN”) appointed Kevin Phelps as a director to fill a vacancy on the Company’s Board of Directors. Mr. Phelps is not appointed to a specific committee and there is currently no arrangement or agreement between Mr. Phelps and the Company. There is no family relationship between Mr. Phelps and any of the Company’s other directors or officers.
Mr. Phelps is a finance and business development professional who has spent his career determining, satisfying and managing the operational needs of a wide range of companies. He is a Certified Public Accountant and holds a BS from the University of Notre Dame. With more than 25 years of broad, professional experience, Mr. Phelps has been in senior management positions raising capital for startup companies, managing financial organizations, and developing new businesses through technology, strategic alliances, and acquisition projects for the past 10 years.
About Immune Therapeutics, Inc. (OTCMKTS:IMUN)
Immune Therapeutics, Inc. is a biotechnology company. The Company is involved in the manufacturing, distribution and marketing of therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system using its patented immunotherapy. The Company’s products and immunotherapy technologies are designed to improve the treatment of cancer, infections, such as human immunodeficiency virus (HIV)/acquired immuno deficiency syndrome (AIDS), chronic inflammatory diseases and autoimmune diseases. Its technology platform is built on various immunotherapies, such as Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK). Its technology offers treatment for a range of cancers. The Company’s clinical programs involve immunotherapy with Methionine-Enkephalin (MENK) (sometimes referred to as opioid growth factor) and its Low Dose Naltrexone (LDN) product or LodonalTM, which stimulates the immune system even in patients with advanced cancer.
